Abstract
We examined patient and treating physician (general practitioners, urologists, and [uro]gynecologists) preferences for oral pharmacotherapy (antimuscarinics and beta-3 adrenoceptor agonists) for overactive bladder to gain a deeper understanding of which attributes drive their treatment decision-making and to quantify to what extent. Two separate discrete choice experiments were developed and validated using the input of patients and physicians. The patient experiment contained the following attributes: micturition frequency, incontinence, nocturia, urgency, dry mouth, constipation, increased heart rate, and increased blood pressure. The physician experiment contained two additional attributes: coping and atrial fibrillation. Both were fielded in five European countries. To allow for preference heterogeneity, utility functions were estimated using a mixed multinomial logit model. A total of 442 patient and 318 physician responses were analyzed. Patients ranked the attributes based on their largest potential impact on treatment value as follows: incontinence, nocturia, risk of an increased heart rate, urgency, frequency, risk of increased blood pressure, risk of constipation, and risk of dry mouth; and physicians as follows: inco...Continue Reading
References
Oct 5, 1993·PharmacoEconomics·M C ReillyE M Dukes
Jun 2, 2000·BMJ : British Medical Journal·M Ryan, S Farrar
Dec 21, 2000·JAMA : the Journal of the American Medical Association
Jun 20, 2001·BJU International·I MilsomA J Wein
Aug 9, 2001·Annals of Medicine·R Rabin, F de Charro
Sep 11, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·K CoyneP Abrams
Feb 1, 2003·Urology·Paul AbramsUNKNOWN Standardisation Sub-Committee of the International Continence Society
Jun 18, 2003·World Journal of Urology·W F StewartA J Wein
Feb 7, 2004·BJU International·C R ChappleUNKNOWN YM-905 Study Group
Nov 13, 2004·The Journal of Urology·V WatsonM Emberton
Nov 17, 2005·BJU International·Yukio HommaUNKNOWN Neurogenic Bladder Society Committee
Feb 8, 2006·European Urology·Karin S CoynePaul Abrams
Nov 11, 2006·Neurourology and Urodynamics·Martin C MichelMartin Burkart
Oct 17, 2007·The Journal of Urology·Spencer E HarpeJames W McAuley
Dec 17, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Tracey YoungKarin Coyne
Oct 13, 2009·BJU International·Rufus CartwrightVik Khullar
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John F P BridgesJosephine Mauskopf
Mar 29, 2012·Female Pelvic Medicine & Reconstructive Surgery·Jennifer M WuMiriam Kuppermann
Oct 27, 2012·The Journal of Urology·E Ann GormleyUNKNOWN Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·F Reed JohnsonJohn F P Bridges
May 23, 2013·International Journal of Clinical Practice·V W NittiN E Martin
Feb 4, 2014·European Urology·Arnav AgarwalKari A O Tikkinen
Jan 28, 2015·The Journal of Urology·E Ann GormleyUNKNOWN Society of Urodynamics, Female Pelvic Medicine
Citations
May 8, 2019·Journal of General Internal Medicine·Ethan M BalkPeter C Jeppson
Jul 28, 2019·International Urogynecology Journal·Frances C HsuMarian S McDonagh
Jun 29, 2017·Drugs & Aging·Veerle H DecalfKarel C M M Everaert
Jun 25, 2017·The Patient·Mike HerdmanNancy Devlin
Dec 10, 2020·Health Economics Review·Gregory MerloLisa Hall
Feb 11, 2021·Neurourology and Urodynamics·Sumedha ChhatreRavishankar Jayadevappa
Jul 17, 2021·Patient Preference and Adherence·Jinender KumarKathleen Beusterien